Comparison of immunoadjuvant activities of four bursal peptides combined with H9N2 avian influenza virus vaccine
10.4142/jvs.2018.19.6.817
- Author:
Cong ZHANG
1
;
Jiangfei ZHOU
;
Zhixin LIU
;
Yongqing LIU
;
Kairui CAI
;
Tengfei SHEN
;
Chengshui LIAO
;
Chen WANG
Author Information
1. Key Laboratory of Veterinary Biological Engineering, Henan University of Science and Technology, Luoyang 471023, China. wangchen2001@163.com
- Publication Type:Original Article
- Keywords:
adjuvants;
bursal peptides-(I–IV);
cellular immune response;
humoral immune response;
immune protection
- MeSH:
Adjuvants, Immunologic;
Animals;
Antibodies, Neutralizing;
Antibody Formation;
Birds;
Bursa of Fabricius;
Cytokines;
Immunity, Cellular;
Immunity, Humoral;
Influenza A Virus, H9N2 Subtype;
Influenza in Birds;
Lung;
Mice;
Peptides;
T-Lymphocytes, Cytotoxic
- From:Journal of Veterinary Science
2018;19(6):817-826
- CountryRepublic of Korea
- Language:English
-
Abstract:
The bursa of Fabricius (BF) is a central humoral immune organ unique to birds. Four bursal peptides (BP-I, BP-II, BP-III, and BP-IV) have been isolated and identified from the BF. In this study, the immunoadjuvant activities of BPs I to IV were examined in mice immunized with H9N2 avian influenza virus (AIV) vaccine. The results suggested that BP-I effectively enhanced cell-mediated immune responses, increased the secretion of Th1 (interferon gamma)- and Th2 (interleukin-4)-type cytokines, and induced an improved cytotoxic T-lymphocyte (CTL) response to the H9N2 virus. BP-II mainly elevated specific antibody production, especially neutralizing antibodies, and increased Th1- and Th2-type cytokine secretion. BP-III had no significant effect on antibody production or cell-mediated immune responses compared to those in the control group. A strong immune response at both the humoral and cellular levels was induced by BP-IV. Furthermore, a virus challenge experiment followed by H&E staining revealed that BP-I and BP-II promoted removal of the virus and conferred protection in mouse lungs. BP-IV significantly reduced viral titers and histopathological changes and contributed to protection against H9N2 AIV challenge in mouse lungs. This study further elucidated the immunoadjuvant activities of BPs I to IV, providing a novel insight into immunoadjuvants for use in vaccine design.
